Literature DB >> 32250377

One-stop radiotherapeutic targeting of primary and distant osteosarcoma to inhibit cancer progression and metastasis using 2DG-grafted graphene quantum dots.

Fu-I Tung1, Lu-Jun Zheng, Kai-Ting Hou, Chih-Sheng Chiang, Ming-Hong Chen, Tse-Ying Liu.   

Abstract

The application of radiotherapy (RT) to treat osteosarcoma (OS) has been limited, but this is starting to change as the ability to target radiation energy to niches improves. Furthermore, lung cancer from highly metastatic OS is a major cause of death, so it is critical to explore new strategies to tackle metastasis. In this study, we designed a nanoscale radiosensitizer by grafting 2-deoxy-d-glucose (2DG) onto graphene quantum dots (GQD) to achieve OS targeting and boost RT efficacy. Combining the use of 2DG-grafted GQDs (2DG-g-GQD) with RT produced a significant increase in oxidative stress response and DNA damage in the 143B OS cell line compared with RT alone. Moreover, 2DG-g-GQDs selectively associated with 143B cells, and demonstrated the inhibition of migration in a scratch assay. We also demonstrated remarkable improvement in their ability to inhibit tumour progression and lung metastasis in an OS xenograft mouse model. Our results show that the use of 2DG-g-GQDs as OS-targeting radiosensitizers improves their therapeutic outcome and exhibits potential for use in low-dose precision RT for OS.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32250377     DOI: 10.1039/c9nr10823h

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  2 in total

Review 1.  LncRNA MALAT1-related signaling pathways in osteosarcoma.

Authors:  Maryam Farzaneh; Sajad Najafi; Omid Anbiyaee; Shirin Azizidoost; Seyed Esmaeil Khoshnam
Journal:  Clin Transl Oncol       Date:  2022-07-06       Impact factor: 3.340

Review 2.  Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma.

Authors:  Kunzhe Wu; Beibei Yu; Di Li; Yangyang Tian; Yan Liu; Jinlan Jiang
Journal:  Front Oncol       Date:  2022-02-15       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.